Actinium Pharmaceuticals Inc (ATNM) 13F Ownership Report (Q2 2026)

ATNM ranks #6222 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ATNM is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

49 institutions disclose a position in ATNM, but none treat it as a major bet — even Compass Financial Management LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Acadian Asset Management LLC has trimmed its ATNM position for two straight quarters, cutting it by $338.0K while still holding $485.0K.

ATNM posted net income of $11.3M over the trailing twelve months, and currently trades at a P/E of 3.4.

• Profitable — net income of $11.3M over the trailing twelve months
• Revenue grew 3306.8% year over year
• Net income improved year over year, from -$41.0M to $11.3M
• Operating cash flow was negative, using $24.6M in cash
• Current ratio of 6.20x — enough short-term assets to cover short-term liabilities
• Liabilities run 5.61x equity — a highly leveraged balance sheet worth noting